CAMBRIDGE, MA--(Marketwired - May 13, 2013) - Selventa today announced that Frost & Sullivan has named Selventa as the winner of its 2013 Technology Leadership Award for the company's Systems Diagnostics (SysDx™) approach to diagnostic testing.

In order to deliver true personalized medicine and solve the problem of disease complexity, physicians will require diagnostics that holistically integrate and interpret multiple types of biological data. Selventa's SysDx works by analyzing a holistic range of a patient's molecular information (e.g., genomic, epigenomic, transcriptomic, proteomic, metabolomic, and electronic medical record information) to identify a panel of "multi-omic" biomarkers that can accurately diagnose a patient's disease and response or non-response to a therapy. SysDx is already used by several large pharmaceutical companies to develop companion diagnostics (CDx) that match patients to their drugs.

"Selventa's discovery platform enables identifying and stratifying the subjects with the aim to define a panel of biomarkers indicating the events propelling the disease mechanisms," said Frost & Sullivan Sr. Research Analyst Cecilia Van Cauwenberghe. "Frost & Sullivan recognizes the outstanding work carried out by Selventa and its commitment to providing real world solutions to its customers, significantly fueling the paradigm shift in the healthcare industry."

"We are honored to win this industry award recognizing the high value of a SysDx approach to diagnostics," said Dr. David de Graaf, CEO of Selventa. "A SysDx multi-omics approach will provide a more detailed picture of patients' disease states than current omics-based tests, which are largely limited to the analyses of genetic aberrations."

"The molecular drivers of disease are manifested across thousands of interrelated biochemical pathways. Therefore, it is vital that a diagnostic be able to test for a more comprehensive set of disease-relevant biomarkers. This is what SysDx does, and why it is an exciting development for the healthcare industry," added de Graaf.

Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in the following categories: innovative element of the product, leverage of leading edge technologies, value added features/benefits, increased customer ROI and customer acquisition/penetration potential.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research in order to identify best practices in the industry.

About System Diagnostics (SysDx)

SysDx testing is a much needed progression from 'single-omic' tests that today are largely limited to the analyses of genetic aberrations in a patient's disease. As the molecular drivers of disease are intertwined across thousands of interrelated biochemical pathways, it is vital that a diagnostic be able to test for a more comprehensive set of disease-relevant biomarkers. SysDx testing promises to capture a more detailed profile of a patient's disease leading to superior predictive and prognostic healthcare decisions.

About Selventa
Selventa is pioneering the development of Systems Diagnostics (SysDx™). This novel approach to diagnostic development harnesses a comprehensive range of complex, biological information (genomic, epigenomic, transcriptomic, proteomic, metabolomic, electronic medical records) to generate a clinically relevant dashboard that physicians, patients and researchers can use to make an optimal treatment decision or stratify patient populations.

SysDx tests are enabled by Selventa's "Big Data" analytics engine that integrates, processes, and analyzes the molecular information from thousands of patients to identify biomarkers linked to disease-driving mechanisms. SysDx tests are differentiated by their ability to capture a holistic picture of a patient's disease and drug-response profile. This is in contrasts to MDx tests that are limited by their focus on a particular class of biological analytes (e.g. genomics-only tests). This superior predictive and prognostic value is required in the diagnosis of complex multi-factorial diseases such as autoimmune disease and cancer.

For more information, visit

Contact Information:

For more information, please contact:
Diane H. Song, Ph.D.
617-547-5421 x235

Constantine Theodoropulos
Base Pair Group